<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05041764</url>
  </required_header>
  <id_info>
    <org_study_id>21DSP-IPMC01</org_study_id>
    <nct_id>NCT05041764</nct_id>
  </id_info>
  <brief_title>RNA Sequencing of Individual Versus Wastewater - SARS-CoV2</brief_title>
  <acronym>Cagablea</acronym>
  <official_title>A Comparison Between Individual and Wastewater SARS-CoV2 RNA Sequencing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre National de la Recherche Scientifique, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim is to compare the percentage of the different SARS-CoV2 lineages that are detected in&#xD;
      wastewater samples with matched clinical samples. About 1,400 swab samples from patients&#xD;
      living in Nice were tested by Biogroup between Oct 19th and Oct 23rd (Week 43 of 2020). The&#xD;
      sequence of 81 PCR positive samples, corresponding to all samples that were unambiguously&#xD;
      assigned to one of the wastewater catchment areas and their lineage was determined. These&#xD;
      values were compared to values measured in wastewater.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Actual">November 1, 2020</completion_date>
  <primary_completion_date type="Actual">November 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>RTqPCR result</measure>
    <time_frame>1 month</time_frame>
    <description>positive ou negative result to SAR-Cov2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SARS-CoV2 sequence</measure>
    <time_frame>1 month</time_frame>
    <description>analyse of SARS-CoV2 sequence (in the case of positive samples)</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1409</enrollment>
  <condition>Infection Viral</condition>
  <arm_group>
    <arm_group_label>PCR positive</arm_group_label>
    <description>samples that are positive for the detection of SARS-CoV2. The SARS-CoV2 sequence of positive samples is provided, together with an indication about patient's neigborhood, corresponding to one of the 21 different spots which wastewater was analyzed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCR negative</arm_group_label>
    <description>samples that are p negative for the detection of SARS-CoV2. T</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NO INTERVENTION</intervention_name>
    <description>No INTERVENTION</description>
    <arm_group_label>PCR negative</arm_group_label>
    <arm_group_label>PCR positive</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        nice population&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  whole population tested in Nice during W43 of 2020&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nice Hospital</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ipmc . Cnrs</name>
      <address>
        <city>Sophia Antipolis</city>
        <zip>06</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 3, 2021</study_first_submitted>
  <study_first_submitted_qc>September 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2021</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

